drugset / Trial / NCT00975507

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

NCT00975507

Phase 3 Completed 480 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.

Timeline

Start
1998-03
Primary completion
1999-01
Completion
1999-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator M-M-R II Vaccine 0.5 ml Subcutaneous
Subject ProQuad Vaccine 0.5 ml Subcutaneous
Comparator Varivax Vaccine 0.5 ml Subcutaneous